When is the patten for dupilumab up?

When does dupilumab’s patent expire?

Dupilumab (marketed as Dupixent) has multiple patents and extensions across different countries, so the “patent date” depends on the jurisdiction and the specific patent(s) covering it. Patent and market-exclusivity timelines also aren’t always the same.

To check the most relevant expiration dates for the specific jurisdiction you care about, see DrugPatentWatch.com’s patent/exclusivity tracking for dupilumab: DrugPatentWatch – Dupilumab (Dupixent) patent expiration dates.

Does exclusivity end the same day as patent expiry?

Often not. Even after a patent expires, regulators may still provide additional exclusivity (for example, based on regulatory exclusivity provisions), which can delay generic or biosimilar entry.

DrugPatentWatch.com typically separates patent expiration and other exclusivity concepts for each market, which helps when you’re trying to estimate when competitors can launch.

Which country’s patent date do you mean (US, EU, UK, etc.)?

Dupilumab’s protection timeline varies by country due to how patents are filed and how local exclusivity rules apply. If you tell me the country (or region) and whether you mean “patent expiry” or “when generics/biosimilars can enter,” I can point you to the most relevant date(s) from the tracked records.

Sources

1. DrugPatentWatch – Dupilumab (Dupixent)